Showing 893 results
-
Media Release /“Stand Together for AD: Strength and Support for Alzheimer’s” at AlzheimersDisease.com empowers caregivers with new resources and tools to help navigate challenges of caring for a loved one with…
-
Media Release /- Review of data from more than 12,000 people in Cystic Fibrosis Foundation's Patient Registry shows 21% mortality reduction in patients treated with TOBI- TOBI is a widely used inhaled antibiotic…
-
Media Release /Gilenya is the first approved oral treatment indicated for relapsing forms of MS in the US, a major advance for people with this diseaseGilenya showed superior efficacy by reducing relapses by 52% at…
-
Media Release /- In a clinical trial, Amturnide demonstrated significantly greater reductions in blood pressure compared to all dual combinations of its components- Amturnide combines the only approved direct renin…
-
Media Release /EAST HANOVER, N.J., Dec. 6, 2010 /PRNewswire/ -- Fewer patients taking Tasigna for Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase progressed to advanced stages of the…
-
Media Release /Elimination of 1,400 General Medicines field force positions effective January 1 to align organization with changes in portfolio and evolving healthcare market New organizational alignment creates…
-
Media Release /Gilenya delayed the progression of disability both for patients who were previously treated for their MS and for patients who had not received prior treatment11 scientific abstracts on Gilenya…
-
Media Release /Phase III program demonstrated significant improvement in lung function lasting for 24 hours and supported safety and tolerability profile of QAB149[1]COPD is a progressive and life-threatening lung…
-
Media Release /East Hanover, NJ, January 10, 2011 – Novartis Pharmaceuticals Corporation (Novartis) has become aware of a United States market recall of all lots of alcohol prep pads, swabs and swabsticks…
-
Media Release /Two pivotal Phase III studies showed ACZ885 may meet significant unmet need for patients for whom many standard therapies are inadequate or inappropriate1,2Regulatory filings for the use of ACZ885 in…
